NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Annovis Bio's Open-Label Extension Study for Buntanetap in Parkinson's Disease
TL;DR
Annovis Bio's extension study offers investors early insight into buntanetap's long-term potential, positioning the company ahead in the neurodegenerative therapy market.
Annovis Bio will conduct an open-label extension study starting January 2026 to monitor buntanetap's safety, efficacy, and biomarker data in Parkinson's patients.
This study advances treatments for neurodegenerative diseases, potentially improving quality of life for Parkinson's patients and their families.
Annovis Bio is exploring buntanetap's disease-modifying potential through extended research on motor and cognitive function in Parkinson's disease.
Found this article helpful?
Share it with your network and spread the knowledge!
Annovis Bio announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson's disease.
Buntanetap is Annovis Bio's investigational therapy that targets multiple neurotoxic proteins, with the goal of addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's to restore brain function and improve patients' quality of life.
The study will be initiated in January 2026.
The study will provide continued access to buntanetap for participants from prior clinical trials of the therapy.
The study aims to enable extended monitoring of safety outcomes, assess sustained effects on motor and cognitive function, and collect biomarker data to support further evaluation of buntanetap's potential as a disease-modifying therapy.
Annovis Bio is headquartered in Malvern, Pennsylvania.
This study represents continued evaluation of buntanetap's potential as a disease-modifying therapy for neurodegenerative disorders, which could restore brain function and improve quality of life for patients.
For more information, visit the company's website at www.AnnovisBio.com, and their social channels on LinkedIn, X, and YouTube.
The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
BioMedWire is a specialized communications platform focused on developments in Biotechnology, Biomedical Sciences, and Life Sciences sectors, and it's part of IBN's Dynamic Brand Portfolio that provides corporate communications solutions to help companies reach investors, journalists, and the public.
Curated from InvestorBrandNetwork (IBN)
